Press Releases

Press Releases

Date Title
08/10/20 Vaxart Announces IND Filed for COVID-19 Vaccine
SOUTH SAN FRANCISCO, Calif. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its COVID-19 Investigational New Drug (IND) application has been
08/06/20 Vaxart Announces Second Quarter 2020 Results
Enhanced Leadership – New CEO in Q2 Ample Cash Runway following Financing by Notable Institutional Healthcare Investors SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by
07/16/20 Norovirus Gastroenteritis Costs an Estimated $10.6 Billion Each Year in the United States
Over 90% of norovirus' total annual cost is due to sporadic spread in the community. SOUTH SAN FRANCISCO, Calif. , July 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than
07/13/20 Vaxart Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility
RA Capital Management to own approximately 9.99% of the Company’s outstanding common stock SOUTH SAN FRANCISCO, Calif. , July 13, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by
06/26/20 Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed
OWS to Test First Oral COVID-19 Vaccine in Non-Human Primates SOUTH SAN FRANCISCO, Calif. , June 26, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that its oral
06/25/20 Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year Through Large Scale Lyophilization, Tableting and Coating SOUTH SAN FRANCISCO, Calif. , June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral
06/24/20 Vaxart, Inc. Set to Join Russell 3000® Index
SOUTH SAN FRANCISCO, Calif. , June 24, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it has joined the broad-market Russell
06/23/20 Vaxart, Inc. to Present at the H.C. Wainwright Virtual Fireside Chat Series
Live Webcast on Thursday June 25th at 10:25 am ET SOUTH SAN FRANCISCO, Calif. , June 23, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced
06/15/20 Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs
Andrei Floroiu Appointed Chief Executive Officer Wouter Latour , MD, to Continue as Chairman of the Board SOUTH SAN FRANCISCO, Calif. , June 15, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NasdaqCM: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant
06/03/20 Vaxart to Present at the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , June 03, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc.  (“ Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced today announced that